40 related articles for article (PubMed ID: 10417342)
1. Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.
Dupont DM; Madsen JB; Hartmann RK; Tavitian B; Ducongé F; Kjems J; Andreasen PA
RNA; 2010 Dec; 16(12):2360-9. PubMed ID: 20962041
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.
Dong Z; Saliganan AD; Meng H; Nabha SM; Sabbota AL; Sheng S; Bonfil RD; Cher ML
Neoplasia; 2008 May; 10(5):439-49. PubMed ID: 18472961
[TBL] [Abstract][Full Text] [Related]
3. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity.
Shi Z; Stack MS
Biochem J; 2007 Oct; 407(2):153-9. PubMed ID: 17880283
[TBL] [Abstract][Full Text] [Related]
4. Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment.
Fishman DA; Kearns A; Larsh S; Enghild JJ; Stack MS
Biochem J; 1999 Aug; 341 ( Pt 3)(Pt 3):765-9. PubMed ID: 10417342
[TBL] [Abstract][Full Text] [Related]
5. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
Fischer K; Lutz V; Wilhelm O; Schmitt M; Graeff H; Heiss P; Nishiguchi T; Harbeck N; Kessler H; Luther T; Magdolen V; Reuning U
FEBS Lett; 1998 Oct; 438(1-2):101-5. PubMed ID: 9821967
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
[TBL] [Abstract][Full Text] [Related]
7. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
8. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin efficiently inhibits tumor cell invasion and metastasis.
Kobayashi H; Sugino D; She MY; Ohi H; Hirashima Y; Shinohara H; Fujie M; Shibata K; Terao T
Eur J Biochem; 1998 May; 253(3):817-26. PubMed ID: 9654084
[TBL] [Abstract][Full Text] [Related]
9. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
[TBL] [Abstract][Full Text] [Related]
10. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma.
Stack MS; Ellerbroek SM; Fishman DA
Int J Oncol; 1998 Mar; 12(3):569-76. PubMed ID: 9472094
[TBL] [Abstract][Full Text] [Related]
11. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer.
Tanimoto H; Yan Y; Clarke J; Korourian S; Shigemasa K; Parmley TH; Parham GP; O'Brien TJ
Cancer Res; 1997 Jul; 57(14):2884-7. PubMed ID: 9230195
[TBL] [Abstract][Full Text] [Related]
12. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells.
Fishman DA; Bafetti LM; Stack MS
Invasion Metastasis; 1996; 16(3):150-9. PubMed ID: 9186550
[TBL] [Abstract][Full Text] [Related]
13. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
14. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin.
Moser TL; Pizzo SV; Bafetti LM; Fishman DA; Stack MS
Int J Cancer; 1996 Sep; 67(5):695-701. PubMed ID: 8782661
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
